Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Physical Urticaria

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    39 result(s) found for: Physical Urticaria. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2020-003018-11 Sponsor Protocol Number: CQGE031E12301 Start Date*: 2021-10-12
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, randomized, double-blind, placebo controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Inducible Urticaria (CINDU) in adolesce...
    Medical condition: Chronic Inducible Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10009869 Cold urticaria PT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10008675 Cholinergic urticaria LLT
    23.0 10040785 - Skin and subcutaneous tissue disorders 10012521 Dermographism LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) SI (Completed) NL (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) GR (Completed) IT (Prematurely Ended) BG (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-006133-32 Sponsor Protocol Number: P04685 Start Date*: 2006-09-20
    Sponsor Name:Allergie-Centrum-Charité
    Full Title: An exploratory phase IV, randomised, double-blind, placebo controlled crossover study to assess and compare the effects of 5 mg vs. 20 mg Desloratadine on the development of experimentally induced ...
    Medical condition: Acquired cold urticaria (ACU) is a frequent form of physical urticaria that is characterized by the development of wheal and flare type skin reactions after cold exposure.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046741 Urticaria cold LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005615-87 Sponsor Protocol Number: CIGE025EDE17T Start Date*: 2012-11-06
    Sponsor Name:Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin
    Full Title: A multicenter, randomized, double-blind, placebo-controlled 12-week, parallel-group study with a 6 week follow up period to demonstrate efficacy and safety of subcutaneous Omalizumab in patients wi...
    Medical condition: Urticaria factitia
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004858 10012499 Dermatographic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-009498-87 Sponsor Protocol Number: Q4577g Start Date*: 2009-06-25
    Sponsor Name:Genentech, Inc.
    Full Title: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study Of Xolair (Omaluzimab) In Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Anith...
    Medical condition: Chronic Idiopathic Urticaria
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009159 Chronic urticaria LLT
    9.1 10021247 Idiopathic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003746-41 Sponsor Protocol Number: CIGE025EDE14T Start Date*: 2012-01-12
    Sponsor Name:Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin
    Full Title: A two-center, double blind, placebo-controlled study in parallel design to assess the efficacy and safety of 150 and 300 mg omalizumab in subjects with antihistamine-resistant cold contact urticari...
    Medical condition: Cold contact urticaria
    Disease: Version SOC Term Classification Code Term Level
    15.1 10040785 - Skin and subcutaneous tissue disorders 10009869 Cold urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006447-95 Sponsor Protocol Number: CDX0159-07 Start Date*: 2022-09-09
    Sponsor Name:Celldex Therapeutics
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose ranging Study to Assess the Efficacy and Safety of CDX-0159 in Patients with Chronic Inducible Urticaria
    Medical condition: Chronic Inducible Urticaria
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004858 10012499 Dermatographic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Ongoing) DE (Ongoing) PL (Ongoing) ES (Ongoing) LT (Ongoing) HU (Ongoing) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002749-38 Sponsor Protocol Number: BT0800NED001 Start Date*: 2007-07-18
    Sponsor Name:Barrier Therapeutics nv
    Full Title: A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticaria
    Medical condition: Chronic Idiopathic Urticaria
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012013-22 Sponsor Protocol Number: BILA-3009/PED Start Date*: 2009-12-09
    Sponsor Name:FAES FARMA S.A.
    Full Title: A Multicentre, International, Adaptive, Open-label, Repeated Administration Pharmacokinetic Study of Bilastine in Children from 2 to <12 Years of age with Allergic Rhinoconjunctivitis or Chronic Ur...
    Medical condition: Allergic Rhinoconjunctivitis and chronic urticaria
    Disease: Version SOC Term Classification Code Term Level
    12.0 10001728 Allergic rhinoconjunctivitis LLT
    12.0 10009159 Chronic urticaria LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002582-37 Sponsor Protocol Number: CS001/2005 Start Date*: 2006-01-13
    Sponsor Name:Allergie-Centrum-Charité Universitätsmedizin Berlin
    Full Title: Characterization of protective effects of a piperidine derivative (DPMP, 4-diphenylmethoxy-1 [3-(4-ter-butylbenzoyl)-propyl] piperidine) on cognitive impairment in urticaria patients
    Medical condition: Urticaria is a very frequent skin condition characterised by transient wheal and flare type skin reactions associated with severe pruritus. In Europe alone, more than 5 million patients are thought...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003011-26 Sponsor Protocol Number: BILA-4021/PED Start Date*: 2021-10-26
    Sponsor Name:FAES FARMA S.A.
    Full Title: A multicentre, open-label clinical trial to assess plasma levels and safety of bilastine in children from 2 to 5 years of age with seasonal and/or perennial allergic rhinoconjunctivitis or urticaria
    Medical condition: Allergic rhinoconjunctivitis. Urticaria.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10046735 Urticaria PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-006413-11 Sponsor Protocol Number: CDX0159-06 Start Date*: 2022-07-27
    Sponsor Name:Celldex Therapeutics
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Assess the Efficacy and Safety of CDX-0159 in Patients with Chronic Spontaneous Urticaria
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10009159 Chronic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) HU (Ongoing) ES (Ongoing) PL (Ongoing) EE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001213-12 Sponsor Protocol Number: HGT-FIR-096 Start Date*: 2014-09-05
    Sponsor Name:Shire Orphan Therapies, Inc.
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety and Efficacy of Icatibant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE...
    Medical condition: ACE-I-induced angioedema
    Disease: Version SOC Term Classification Code Term Level
    17.0 10040785 - Skin and subcutaneous tissue disorders 10002424 Angioedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004094-93 Sponsor Protocol Number: PAFCUTIII Start Date*: 2012-04-19
    Sponsor Name:Allergie-Centrum Charité
    Full Title: Double-blind, three-way cross-over, placebo controlled study to assess the efficacy, safety and mechanisms of treatment with rupatadine 20 and 40mg in cold contact urticaria (CCU)
    Medical condition: Cold contact urticaria
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10009869 Cold urticaria LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-001796-17 Sponsor Protocol Number: TV45779-IMB-30086 Start Date*: 2021-11-30
    Sponsor Name:Teva Pharmaceuticals, Inc.
    Full Title: A Multinational, Multicenter, Randomized, Double Blind Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of TEV-45779 Compared to Omalizum...
    Medical condition: Chronic Idiopathic Urticaria/Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020197 Hives LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) PL (Completed) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004002-10 Sponsor Protocol Number: UFD-DESIC-001 Start Date*: 2012-12-10
    Sponsor Name:Department of Dermatology and Allergology, University of Szeged
    Full Title: Comparison of the effectiveness of desloratadine monotherapy and the combined cinnarizine and iprazochrome therapy for the treatment of urticaria factitia
    Medical condition: Among physical urticaria patients about 20-30% have urticaria factitia. The pathomechanism of urticaria factitia is not clear. Antihistamines are used to treat the condition, and this is in accorda...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002669-16 Sponsor Protocol Number: GA43512 Start Date*: 2022-04-04
    Sponsor Name:Genentech Inc.
    Full Title: A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT AND DOSE-RANGING STUDY OF MTPS9579A IN PARTICIPANTS WITH REFRACTORY CHRONIC SPONTANEOUS URTICARIA
    Medical condition: Refractory Chronic Spontaneous Urticaria
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005726-30 Sponsor Protocol Number: CURES-IL1T-OT-1236 Start Date*: 2014-04-28
    Sponsor Name:Charité - Universitätsmedizin
    Full Title: A multi-center, double-blind placebo-controlled parallel group phase II study of the efficacy and safety of rilonacept in subjects with cold contact urticaria (CCU)
    Medical condition: cold contact urticaria (CCU)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004624-35 Sponsor Protocol Number: GS39684 Start Date*: 2017-05-10
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT AND DOSE-RANGING STUDY OF GDC-0853 IN PATIENTS WITH REFRACTORY CHRONIC SPONTANEOUS URTICARIA (CSU)
    Medical condition: Chronic spontaneous urticaria (CSU)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003506-27 Sponsor Protocol Number: BILA-3312/PED Start Date*: 2013-01-25
    Sponsor Name:FAES FARMA, S.A.
    Full Title: A multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the safety and tolerability of 10 mg once daily bilastine in children from 2 to 11 years of age with e...
    Medical condition: Allergic Rhinoconjunctivitis and Chronic Urticaria
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing) PT (Completed) PL (Completed) HR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003542-17 Sponsor Protocol Number: CU-LATER Start Date*: 2014-06-11
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: A multi-center, randomized, double blind, dose escalating phase III study on the efficacy, safety and long term outcome of continuous vs. on demand treatment of chronic spontaneous urticaria with r...
    Medical condition: Chronic Spontaneous Urticaria
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:41:53 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA